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UterusUterus transplantation (UTx) is the only available treatment for absolute uterine factor infertility (AUFI),
which is caused by either absence (congenital or after hysterectomy) or presence of a non-functioning
uterus. Uterus transplantation became a clinical reality after more than 10 years of structured animal-
based research. Aside from gestational surrogacy, this procedure is the only alternative for women with
AUFI to attain genetic motherhood. In the Middle East, North Africa and Turkey (MENAT) region, out of a
population of around 470 million, more than 100,000 women of fertile age are estimated to suffer from
AUFI. Introduction of UTx as an infertility treatment in this region will certainly differ in specific countries
from ethical, religious and legal standpoints depending on culture and religion. The MENAT region is the
cradle of three religions and the geographic area encompasses a variety of cultures and religions with dif-
ferent views on assisted reproduction. In light of these issues, the aim of this article is to give an overview
of the research-based development of UTx and its clinical results up until today as well as to explore how
UTx would fit into current infertility treatments in the MENAT region, with its existing multifaceted reli-
gious perspectives.
 2017 Middle East Fertility Society. Production and hosting by Elsevier B.V. This is an open access article
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Absolute uterine factor infertility (AUFI) has for many years
been regarded as untreatable. We reported the first live birth after
UTx in 2014 [1] and this has been followed by more births [2].
Thus, UTx is now established as the first treatment for AUFI. Histor-
ically, there were early attempts to develop UTx with the hope of
reaching clinical application. These experiments included trans-
plantation of grafts including the uterus and the oviducts in dogs
[3] and nonhuman primates during the 1960s and 1970s [4]. The
primary aim was to develop treatment for tubal factor infertility
(TFI) and the uterus was included in the graft to simplify surgery.
However, the lack of effective immunosuppression (IS) drugs at
that time was central in the failure of these pioneering
experiments.
After worldwide spread of IVF in the 1980s, TFI became treat-
able and the interest in UTx-research ceased. Introduction of the
first effective IS, cyclosporine, in the mid-1980s, gave rise to a sub-
stantial expansion of the clinical field of transplantation surgery.
Today even highly immunogenic tissues such as intestines and vas-
cularized composite tissues (hand and face) are transplantable. All
existing types of transplants are intended for lifelong use and with
continued IS. In this regard, UTx is unique as an ephemeral type of
transplantation. Thus, the allograft would just be in the recipient
for a restricted time. After the recipient has delivered the number
of children desired, hysterectomy should be performed. The recip-
ient can then discontinue IS medications and thereby avoid the IS-
related long-term side effects, such as nephrotoxicity [5], as well as
increased risks for serious viral, fungal and bacterial infections and
certain malignancies [6,7]. The two first UTx attempts in the world
were performed in 2000 and 2011 and both took place in the
MENAT region [8,9]. Although, these attempts did not result in
any births, they paved the way for our clinical trial in Gothenburg,
Sweden which included nine patients undergoing UTx in 2013
[10]. The results of all these attempts will be discussed in detail
below.Table 1
Causes of uterine factor infertility that may be treatable by uterus transplantation.
No uterus
 Congenital uterine absence (Müllerian/Mayer-Rokitansky-Küster-Hauser
(MRKH)-syndrome)
 Hysterectomy
– Cervical/uterine malignancy1.1. Potential patient groups for UTx
The causes of permanent AUFI [11] are listed in Table 1. It is
estimated that around 15,000 AUFI patients exist in the UK [12]
and this would, on a population-basis, correspond to around
100,000 in the MENAT region.– Leiomyoma
– Obstetric bleeding
– Atony
– Malplacentation (placenta accrete/percreta)
– Uterine rupture
Uterus present
 Leiomyoma
 Adenomyosis
 Multiple miscarriages/implantation failures
 Radiation damage
 Uterine malformation
– Fraction of unicornuate uterus
– Fraction of bicornuate uterus
– Hypoplastic uterus
 Cervical incompetence with multiple miscarriages
– Post multiple conisation procedures
– Post trachelectomy procedure
 Severe intrauterine adhesions, untreatable by hysteroscopy1.2. Guidelines for research and development towards human UTx
The modern research preparations in UTx span over more than
a decade [13,14] and follow the IDEAL (Innovation, Development,
Exploration, Assessment, Long-term follow up) concept [15], which
emphasizes a structured and research-based introduction of any
novel, major surgical procedure. This approach minimizes the risks
for the patients but also accumulates important scientific data dur-
ing clinical introduction. Currently, UTx is in the D (Development)
phase of the IDEAL concept with our observational study, including
nine patients [10]. An International Society for Uterus Transplanta-
tion (ISUTx) was recently formed at a meeting in Gothenburg Swe-
den. This society has initiated the formation of an international
registry, to follow all patients (donors, recipients, and children)lease cite this article in press as: R. Akouri et al., Uterus transplantation: An up
x.doi.org/10.1016/j.mefs.2017.04.003to accumulate data to also explore the L (Long-term follow-up)
phase of the IDEAL concept.
It is necessary that information concerning all ongoing human
UTx research and its results reach the public in all countries and
societies so that all are informed about this potential new fertility
treatment, which also may raise some ethical concerns. It should
be mentioned that Federation International Gynecology and
Obstetrics (FIGO) launched ethics principles of UTx already in
2009 and these emphasizes that animal experiments is an obliga-
tory component [16].2. Animal-based UTx research and human UTx
Modern attempts in animal-based UTx research stems from the
early 2000s and initially involved smaller rodents, later large
domestic species and from around 2005 nonhuman primates
[13,14,17]. The key findings of this research are summarized
below.2.1. Rodents
The initial rodent UTx model was the mouse, with the first ever
pregnancy after UTx demonstrated already in 2002 [18] and in
2003 we reported the first offsprings [19]. This was in a syngeneic
setting (between inbred strains) and consequently IS was not
needed. Offspring exhibited normal postnatal growth trajectory
and were fertile. The uterus was tolerable to 24 h of cold ischemia,
between harvesting from the donor until UTx, since the majority of
these cold-preserved and transplanted uteri achieved normal preg-
nancy and offspring [20]. Additional mouse UTx-studies, character-
ized rejection after allogeneic transplantation by examining the
morphology, blood flow [21], influx of specific subclasses of leuko-
cytes [22,23] as well as influence of immunosuppression by cyclos-
porine [24].date and the Middle East perspective, Middle East Fertil Soc J (2017), http://
R. Akouri et al. /Middle East Fertility Society Journal xxx (2017) xxx–xxx 3We introduced the rat UTx model some years later, with the
advantages of this model being the larger size of the vasculature
and that therapeutic blood concentrations of IS are in the same
range as in the human, as opposed to the mouse, with much higher
therapeutic levels. The uterus was transplanted into an orthotopic
position, with vascular anastomoses to the common iliacs, to allow
for natural conception in the initial syngeneic rat-UTx model [25].
Although similar pregnancy rates were noted in the UTx group and
control group, there was a high rate of arrested parturition after
UTx [26]. Studies were also performed to find the optimal IS in
the allogeneic rat UTx model and tacrolimus was found to be supe-
rior to cyclosporine to prevent rejection [27,28]. Pregnancies were
demonstrated after allogeneic UTx under tacrolimus IS and normal
growth of these offspring was seen [29,30].
2.2. Domestic species
Both the pig and sheep have been used in UTx research, with
the advantage being their larger body size and consequently with
dissection of the uterine vasculature that resemble the anatomical
situation in the human. However, a difference is that both these
species have bicornuate uteri. Our initial sheep UTx model was
with excision of one uterine horn and at auto-UTx, anastomosis
was performed to the ipsilateral external iliac vessels [31,32]. After
utero-ovarian autotransplantation, with undisturbed connections
of the utero-tubal-ovarian compartment, mating occurred and live
offsprings were demonstrated [33]. The Ramirez group performed
allogeneic UTx in the sheep, with end-to-end anastomosis on the
uterine vessels and long-term uterine survival was seen with
cyclosporine IS [34]. One live birth was demonstrated in a
follow-up study [35]. Another group showed graft survival for
two months after allogeneic UTx with bilateral end-to-end vascu-
lar anastomoses on uterine arteries/utero-ovarian veins and with
a triple IS protocol of tacrolimus, mycophenolate mofetil (MMF)
and methylprednisolone [36]. In the pig UTx model, initial auto-
UTx studies examined reperfusion events [37] and vascular
patency some weeks after transplantation [12]. In the latter study,
the graft was reintroduced after 1 h of cold storage and this was
followed by stepwise vascular reanastomosis. Graft survival was
seen for 3 months but with signs of gradual thrombosis formation.
Later, long-term survival of the allogeneically transplanted min-
iswine uterus was seen after IS with intra venous tacrolimus for
12 days which was followed cyclosporine and with a transplanta-
tion technique of a macrovascular aorto-caval patch, with the
uterus heterotopically positioned [38].
2.3. Nonhuman primates
The obvious advantage of a nonhuman primate species in UTx
research is the human-like immunology as well as reproductive
anatomy/physiology. In our initial studies utilizing auto-UTx in
the baboon, restored menstruation was only seen in 20% of animals
[39]. After modification of methodology in relation to flushing of
the graft and anastomosis surgery a 3-fold higher success rate
was accomplished [40]. In allogeneic UTx in this species, with
transplantation from live donors, recovery surgery lasted for
3.5 h and donor survival was 100% [41]. The best IS protocol was
induction with antithymocyte globulin, followed by triple mainte-
nance IS with tacrolimus, MMF and corticosteroids [41]. Impor-
tantly, a rejection-grading system, based on histology of cervical
biopsies, was developed in this allogeneic baboon UTx model
[41,42].
Initial studies in the smaller cynomolgus macaque, with bilat-
eral anastomosis of the uterine artery and the deep uterine vein
to the external iliacs demonstrated resumed menstruation [43]. It
was also shown that the complete macaque uterus is adequatelyPlease cite this article in press as: R. Akouri et al., Uterus transplantation: An upd
dx.doi.org/10.1016/j.mefs.2017.04.003perfused with use of only unilateral anastomoses [44]. Impor-
tantly, the first UTx pregnancy and live offspring, albeit after
auto-UTx, in a primate species was shown in the cynomolgus
macaque [45]. Moreover, a surgical procedure using the ovarian
vein for outflow demonstrated adequate perfusion after UTx and
it was concluded that this technique could potentially simplify
live-donor surgery in UTx [46]. However, it should be noted that
pregnancies have not been demonstrated in this model, using the
ovarian veins. A problem may be tension of these veins during
the progressive uterine growth during pregnancy, especially if
the anastomosis sites are on the external iliacs, which are relatively
low in the pelvis. Recently, it was demonstrated that after allo-UTx
in the macaque, with triple IS therapy (tacrolimus, MMF and
methylprednisolone), there was recovery of menstruation around
three months after surgery [47].3. Preclinical human UTx studies
There has been a small number of preclinical UTx studies by the
use of human material. We assessed the tolerability to cold ische-
mia of myometrial tissue-pieces from hysterectomy specimens and
found that the ultramorphology of the myometrial cells were well
preserved after 6 and 24 h of cold ischemia and spontaneous, as
well as prostaglandin-augmented, myometrial contractions were
still present [48]. Two studies investigated uterine recovery from
brain-dead donors. In the initial study, performed in USA, uterine
donation with a research purpose was only accepted by the rela-
tives of the brain-dead women in 6% of cases [49]. The other study
was performed in France, almost a decade later [50], when the con-
cept of human UTx was known to the public after initial success of
human UTx cases [1,9]. In that study, with a much higher (50%)
acceptance rate, organ retrieval procedure was performed in seven
female multiorgan donors. The uterus was removed together with
the hypogastric vessels, parametria, and vaginal fornices. They
found no major morphologic changes in the myometrium after
24 h of cold ischemia and the hypogastric vessels could be pre-
served in all cases but one with unilateral vein loss. Severe desqua-
mation of the endometrium was seen after 24 h of cold ischemia
but apoptotic cells were rare.
In a live donor UTx procedure, it is more difficult to acquire long
vascular pedicles. We explored this issue in a study of patients
undergoing radical hysterectomy surgery and with added separate
dissections of uterine arteries and veins [51]. The accomplished
lengths of the uterine arteries and veins were above 5 cm, which
would enable bilateral end-to-side anastomosis to the external ili-
acs, since they are around 9 cm apart at the level of the uterus [51].4. Human UTx
The first ever attempt of human UTx was performed in Middle
East, more precisely in Jeddah, Saudi Arabia in April 2000 [8].
The donor, a 46-year-old, premenopausal woman presenting with
large bilateral ovarian cysts, underwent hysterectomy and bilateral
salpingo-oophorectomy. The recipient, a 26-year-old woman, had
undergone emergency peripartum hysterectomy due to massive
hemorrhage at a cesarean section six years prior.
Donor hysterectomy was modified with fairly short vascular
pedicles of the uterine arteries and veins. A ureteric laceration
occurred and it was immediately repaired. Upon retrieval, the
uterus with attached oviducts was flushed with cold Euro-Collins
solution. Extensive back-table surgery was performed by anasto-
mosing 6–8 cm long saphenous venous grafts in end-to-end man-
ners on uterine veins and as reversed grafts on uterine arteries.
Laparotomy of the recipient commenced when donor graft
retrieval was imminent. The donor uterus was placed in the ortho-ate and the Middle East perspective, Middle East Fertil Soc J (2017), http://
4 R. Akouri et al. /Middle East Fertility Society Journal xxx (2017) xxx–xxxtopic position with the extended uterine arteries and veins anasto-
mosed end-to-side to the external iliacs. Cyclosporine, corticos-
teroids and azathioprine were used as maintenance IS.
One possible episode of rejection was observed on day nine
post-surgery and was treated by antithymocytic globulin. The
uterus did not show spontaneous menstruation. On day 99 post-
surgery the transplant recipient presented with pelvic heaviness
and vaginal discharge. Doppler examination could not detect uter-
ine blood flow. Hysterectomy was performed and histopathology
confirmed blood flow cessation with infarction. Albeit a graft fail-
ure, this first human UTx case, performed in the Middle East,
advanced the field considerably by demonstrating the feasibility
of uterine donation from a live donor. However, it was clear that
further animal-based research was necessary before any new clin-
ical attempt should be performed.
The second human UTx was also performed in the MENAT
region. In August 2011, a 21-year old MRKH-patient was trans-
planted with a uterus from a 22-year-old brain-dead, heart beating
donor in Antalya, Turkey [9]. The recovery with the uterus as the
first organ to be retrieved, took 2 h and the transplantation proce-
dure, including bilateral end-to-side anastomosis of the common
iliacs of the graft to the recipient’s external iliac vessels, lasted
6 h. The initial IS included daily thymoglobulin for 10 days fol-
lowed by maintenance IS with tacrolimus, prednisolone and
MMF. Today, five years after transplantation, the uterus is still in
place. The multiple ET attempts that have been performed have
resulted in only two early miscarriages [52]. The reason for the
pregnancy failures is not clear but it may well be related to
uterine-specific factors rather than embryo-specific factors, since
the recipient is of young age. Notable is that the young trans-
planted uterus had not carried a pregnancy before UTx, and there
may exist uterine-specific anatomical or biochemical factors that
impair implantation or continued pregnancy.
In Gothenburg, Sweden, we performed nine live-donor UTx pro-
cedures in early 2013 [10]. Eight recipients had the MRKH syn-
drome and one had undergone a radical hysterectomy because of
stage Ib1 cervical cancer. The patients went through 2–3 IVF cycles
prior to UTx in order to cryopreserve embryos. The donors were
mothers in five cases, one older sister, one maternal aunt, one
mother-in-law and one close friend. Five donors that were post-
menopausal received cyclic estrogen-progestagen treatment for
2–3 months before surgery, in order to ensure normal menstrual
patterns and to possibly increase uterine artery blood flow before
donation. The donors, recipients and partners of recipients wereFig. 1. Schematic drawing of the live donor uterus transplantation procedure. The Donor s
segment of the internal iliac arteries and veins. The Uterus (middle) is chilled and flushe
vascular anastomoses to the external iliac artery and vein.
Please cite this article in press as: R. Akouri et al., Uterus transplantation: An up
dx.doi.org/10.1016/j.mefs.2017.04.003extensively investigated for several months before UTx to ensure
that they were medically and psychologically fit for participation
[10,53]. The donor surgery [10] was performed by a midline inci-
sion with initial dissection of the uterus, excluding ovaries and ovi-
ducts, on the frontal aspect to include an extensive bladder
peritoneum. Ureteric dissection, without confronting the adjacent
uterine vessels, was performed from the pelvic brim to the bladder.
Bilateral vascular pedicles, including the internal iliac arteries dis-
tal to the branchings of the gluteal arteries as well as the major
uterine veins down to, and including a part of the internal iliac
vein, were dissected (Fig. 1). The rectovaginal space was then
opened and the uterus, with long bilateral vascular pedicles was
isolated and brought to the back-table (Fig. 1). Donor surgeries
lasted 10.5–13 h, but no perioperative blood transfusions were
required and with hospital stay of 6 days in all cases. In one patient
a ureteric-vaginal fistula was diagnosed two weeks after the hys-
terectomy and this was later successfully repaired.
The recipient surgery included bilateral end-to-side anasto-
moses to the external iliacs, anastomosis to the vagina and uterine
fixation to several pelvic ligaments (Fig. 1). The IS regimen was
induction with two perioperative doses of thymoglobulin. From
the day of surgery also tacrolimus and MMF were given daily
and glucocorticoids were administered for one week. After eight
months, MMF was discontinued if no or only one rejection epi-
sodes had occurred during this period, but was replaced with aza-
thioprine in patients with several rejection episodes. The 6-months
outcome was that seven out of nine uteri were still in place. One
uterus was removed after three days because of bilateral thrombo-
sis of the uterine vessels in a recipient with heterozygocity for the
Leiden mutation. The second uterine removal was because of an
intrauterine infection, that developed into an abscess and sep-
ticemia, despite heavy iv antibiotic treatments and several
attempts of surgical drainage [10]. These two graft failures
occurred in two out of the three uteri that were above age 60 at
transplantation and also in one case with the lowest uterine blood
flow after transplantation.
The seven remaining uteri showed spontaneous and regular
menstruation beginning 1–2 months after UTx [54] and uterine
artery blood flow was within normal ranges. Subclinical, mild
rejection episodes were diagnosed on protocol cervical biopsies
in five out of seven women [54].
The psychological outcome during the first post-transplantation
year of recipients and partners was an overall optimism but with
minor anxiety around graft survival around three months posturgery (Left) involves harvesting of the uterus with long vascular pedicles, including
d on the back-table (central image). The Recipient surgery (right) involves bilateral
date and the Middle East perspective, Middle East Fertil Soc J (2017), http://
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Two women became pregnant at their first ET and the first live
birth after UTx took place September 4, 2014 [1]. Preeclampsia
developed at gestational week 31+5 in this MRKH patient with a
single kidney and delivery was by cesarean section the following
day. Although this was patient number five of the UTx trial and
the seventh UTx attempt worldwide, the case represents the first
UTx procedure that by definition is successful. The second UTx-
baby born was from a mother-to-daughter UTx and delivery of a
healthy baby was by cesarean section in week 34+6 [2]. Preeclamp-
sia did not develop in this mother, with double kidneys. However,
preeclampsia has developed in two out of three of the subsequent
births and only in MRKH mothers with single kidneys (unpub-
lished observations). It is likely that the single kidney is the stron-
gest risk factor for preeclampsia development after UTx, even if the
MRKH-setting and other factors such as aged uterus, IS and IVF
may contribute [56]. So far five out of seven patients from our
cohort that have undergone UTx and ET have delivered healthy
babies, with one giving birth twice. Two more pregnancies our
ongoing and expected to deliver in early summer 2017 (our unpub-
lished data).5. Religious-societal aspects of UTx in the Middle East region
In general, the capacity to have offspring has always been an
undeniably significant aspect of human existence. The ethical lay-
ers of UTx as a clinical treatment will vary depending on the cul-
ture and religion of each specific society. In the Middle East, the
site of origin of the three major religions: Judaism, Christianity
and Islam, the beliefs are stronger than in many other parts of
the world.5.1. Islam and UTx
For Middle Eastern Muslims, formation of family with children
is highly desirable as parenthood is culturally mandatory. In that
regard, many alternative reproductive technologies are being
explored to reduce the effects of infertility. Unlike many other
parts of the world, the new medical technologies are practiced
according to religious guidelines. Not only are Islamic religious
authorities keen to establish the limitations within which ART is
and is not acceptable, but many infertile Muslim couples are also
progressively more open to pursuing ART in seek of parenthood
in the acceptable and religiously endorsed manner. Islam permits
reproduction only using the genetic material of intended parents.
Thus IVF, insemination and embryo cryopreservation, with use of
gametes of its lawfully married parents, are permissible [57]. The
Sunni sect is the most prevalent form of Islam (about 90% of the
world’s Muslims). While, all Sunnis consider surrogacy as prohib-
ited, Shia Muslims believe otherwise. In 1999, a fatwa allowing
donor technologies in ART to be used was introduced in the Islamic
republic of Iran, permiting not only surrogacy but also sperm dona-
tion, egg donation, and embryo donation [58].
Concerning transplantation of reproductive tissues, the Islamic
Fiqh Council conference held in the sixth cycle in Jeddah in Saudi
Arabia in 1990 came to several conclusions after studying the
research and recommendations on the subject, and in collaboration
with the Islamic Organization for Medical Sciences. Transplanta-
tion of gonads (testis and ovary) that carry genetic traits is forbid-
den in Islam. Second, transplantation of parts of the reproductive
system that does not transfer genetic traits e.g. the uterus is legal
and legitimate in accordance with the regulations and standards
set out in the legitimacy. Moreover, the majority of Islamic legal
scholars have concluded that transplantation of organs as treat-
ment for otherwise lethal end-stage organ failure is a good thing.Please cite this article in press as: R. Akouri et al., Uterus transplantation: An upd
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mitted but encouraged [59].
5.2. Christianity and UTx
5.2.1. Catholism
The accustomed principle, referred to in the Catechism of the
Catholic Church, that the morals of an individual act depend on
three factors (the object, the end, and the circumstances) involved,
can be applied on introduction of newmedical technologies. An act
is morally good only if all three of these factors are morally good.
Paragraph 2376 of the Catechism of the Catholic Church states
that: ‘‘Techniques that entail the dissociation of husband and wife,
by the intrusion of a person other than the couple (donation of
sperm or ovum, surrogate uterus), are gravely immoral [60].
Regarding UTx, they state it as ‘‘good” way to restore a woman’s
infertility by transplanting a healthy womb in situations where
she lacks one. But the action by pursuing a pregnancy through
in vitro fertilization (IVF) would render it as immoral, since IVF
represents a morally disordered means of engendering new
human. Only under the circumstances where a transplanted
uterus, either from a deceased or a live donor, to another woman
whose ovaries and Fallopian tubes would function normally so
she could conceive a child by normal way the womb transplant
could probably represent an ethical means of resolving the AUFI
[61].
5.2.2. Orthodox denomination
The Holy Tradition of the Orthodox Church does not refer
directly to new reproductive technologies. Nevertheless, a number
of Orthodox writers have addressed them. These authorities gener-
ally maintain a powerful respect for life as a gift from God. They
furthermore support the Orthodox Church’s view of procreation
within marriage as the proper expression not only of their physical
sexual relationship, but also of whole spiritual, familial, and social
relationships [62]. On the other hand, since death ends the per-
sonal physical relationship of spouses, the Church does not support
various methods of postmortem conception for example implanta-
tion of frozen fertilized ova. One reason given for this prohibition is
the moral, relational, social, and spiritual confusion that such prac-
tices provoke. For similar reasons, the Orthodox Christian Church
also fundamentally opposes all forms of surrogate motherhood
[63], which may speak in favor of UTx.
An Orthodox Christian should not be pressured to violate per-
sonal convictions if they do not wish to donate an organ or receive
an organ transplant, following the provision of adequate informa-
tion. Nevertheless, the Orthodox church would accept organ dona-
tion as a way to better human life to improve and prevent a disease
by using transplantation or research. In some predominantly
Orthodox nations, the Church has supported organizations that
foster the practice of organ transplantation as an expression of phi-
lanthropy and Christian love [64].
5.3. UTx and Judaism
It is the first and the most important bidding in the Torah to be
fruitful and multiply (Genesis 1:28). Infertility is a disorder, so
everything is possible in order to alleviate a patient. It is even per-
mitted to break the laws of Shabbat for cure. It is believed that doc-
tors are God’s hands blessed with special abilities and
understanding to alleviate ailing humans and every Jew has to
yield affliction of his or her health, and has to do his or her bests
to receive the greatest possible treatment. Because of the centrality
of children in Judaism, and the biblical commandment to be fruit-
ful and multiply, infertility is often especially painful for Jewish
couples. Societal norms in the observant Jewish community - suchate and the Middle East perspective, Middle East Fertil Soc J (2017), http://
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larger families with births more closely spaced than is usual in
the general society- can add to the pressure. The biblical com-
mandment is fulfilled, by having one son and one daughter. There-
fore, it is often assumed that couples are attempting to conceive
from the moment of marriage and thus the family and society
may become aware of a fertility problem sooner in this patient
population than in the general public.
In general, the Jewish beliefs have traditionally taken a doubtful
view regarding dead donation. There are three prohibitions con-
cerning cadavers that would seem to prevent deceased organ
donation. These are (a) damaging a cadaver, (b) delaying burial
of a cadaver, and (c) receiving a profit from a cadaver [65]. This
would not apply to the donation of the uterus, which is not a life-
saving organ but unlike any other type of transplantable organ a
life propagating organ.
According to majority of contemporary scholars UTx using
related donor is acceptable in light of the Jewish religious law.
Preferably a donor should be at the post-menopausal state, risks
to both donor and recipient should be limited as much as possible,
and the surgery should be planned well in advance before Shabbat
and holidays.
6. Preparations for the first clinical UTx-center trial in the
Middle East
Our collaborative group was initiated in 2014 to explore the
possibility of performing a trial of UTx in Lebanon. We have
worked extensively with protocols for the procedure and with
transfer of the UTx technology from Sweden to Lebanon. Surgical
training in sheep has been ongoing in Sweden after the human trial
to optimize the technique and we will conduct common surgical
training sessions involving autotransplantation of the sheep
uterus. The sheep is a suitable model, because of similar size of
blood vessels and uterus, as the human. Moreover these autotrans-
plantation procedures mimic both organ procurement from live
donor and uterus transplantation. The most important aspect is
however, the training and exercise of the team work of gynecolo-
gists and transplant surgeons so that every surgeon use their
expertise when needed and in collaboration with other team-
members.
We have chosen to plan for a live donor concept, since surgery
can be planned with participants of both the Swedish team and the
local Lebanese team. It should also be pointed out that a live donor
UTx procedure give ample time for investigations of the suitability
of the uterus to be donated. Moreover, the graft survival in renal
transplantation is in general superior when the organ is from live
donors in comparison to when from deceased donors. This would
most likely also apply to UTx, since the systemic inflammation
with massive cytokine release that occur at brain death is avoided.
The ethics behind live donor UTx have been reviewed [66] and
this is now applied to a setting of the Middle East by ethics discus-
sion and formation of documents. The Bellevue University Medical
Center, Ethical Committee (IRB) recognized by the Lebanese Min-
istry of Public Health has approved this clinical trial pending review
of all medical and psychological files of every case undergoing this
trial to make sure that all ethical requirements are respected.
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